Topic resource collection
Approved comparison material connected to this topic.
3 resourcesRead both sides
PT-141 (bremelanotide) Low sexual desire and related distress in premenopausal women (HSDD); erectile response in men Strong human clinical — FDA-approved for one specific indication Effect size is modest; approved only for preme…
PT-141 (Bremelanotide) Melanocortin receptor agonism → central arousal initiation MC3R, MC4R (hypothalamus) Subcutaneous injection 45–60 minutes 1.75mg subcutaneous Strongest Phase III data for central arousal effects; works inde…
No single resource in the current search landscape compares these peptides against each other. The table below covers mechanism, evidence, suitability, and practical considerations. Mechanism MC4R: dopamine + oxytocin HPG axis + …